Skip to main content

Clinical Pharmacology of Anti-Epileptic Drugs

Workshop on the Determination of Anti-Epileptic Drugs in Body Fluid II (WODADIBOF II) Held in Bethel, Bielefeld, Germany, 24 - 25 May, 1974

  • Conference proceedings
  • © 1975

Overview

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (36 papers)

  1. Pharmacokinetics

  2. Pharmacology of Anti-Epileptic Drugs

    1. Ethotoin

Keywords

About this book

"He who is faithfully analysing ... epi­ lepsy is doing far more than studying epilepsy" Hughlings Jackson Modifying this well-known statement by Jackson, one could say today: "He who is faithfully analysing anti-epileptic drugs is doing far more than studying anti-epileptic drugs". For these drugs not only serve to prevent epileptic fits and thus advance the treatment of epilepsy, they are also effective in the treatment of cardiac arrhythmias and trigeminal neuralgia. Furthermore, clinical pharmacologists consider anti-epi­ leptic drugs as model drugs in pharmacokinetics and pharmocodynamics, since reliable methods are available for their determination and their effects and side­ effects can be defined. The methods of estimating of drugs in body fluids provide a tool that enables us to throw light on many obscure relationships in pharmaceutical treatment. Now that we can study the pharmacokinetics and interaction of drugs in man, many hypotheses based on clinical experience alone may well be eliminated or corroborated. The grow­ ing body of knowledge will make us more careful about the administration of drugs in combination. Now that we can study how biological parameters interfere with drug action, we may perhaps proceed to the scientific analysis of many clinical observations that suggest the importance of such factors as age, sex, menstrual cycle, pregnancy, fever, diet, stress, sport, climate, and altitude.

Editors and Affiliations

  • Neurophysiol. Abtlg., Ges. f. Epilepsie-Fschg. e. V., Bethel, Maraweg 13, Germany

    H. Schneider

  • Abteilung für Neurologie im Klinikum Charlottenburg, Freien Universität Berlin, Berlin 19 (West), Germany

    D. Janz

  • Exeter & Mid-Devon Hospitals, Royal Devon & Exeter Hospitals (Wonford), Exeter, England

    C. Gardner-Thorpe

  • Instituut voor Epilepsiebestrijding, Heemstede, The Netherlands

    H. Meinardi

  • Montreal Neurological Institute, Montreal 112, Canada

    A. L. Sherwin

Bibliographic Information

  • Book Title: Clinical Pharmacology of Anti-Epileptic Drugs

  • Book Subtitle: Workshop on the Determination of Anti-Epileptic Drugs in Body Fluid II (WODADIBOF II) Held in Bethel, Bielefeld, Germany, 24 - 25 May, 1974

  • Editors: H. Schneider, D. Janz, C. Gardner-Thorpe, H. Meinardi, A. L. Sherwin

  • DOI: https://doi.org/10.1007/978-3-642-85921-2

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin-Heidelberg 1975

  • Softcover ISBN: 978-3-642-85923-6Published: 04 April 2012

  • eBook ISBN: 978-3-642-85921-2Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XII, 370

  • Topics: Pharmacology/Toxicology, Pharmacy, Medicine/Public Health, general

Publish with us